ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

New GAO Report Critical Of federal Effort Against Environmental Carcinogenesis

June 25, 1976

ACS Challenged To Clarify Position On FDA Reform

March 1, 1996

FDA Seeks Consumers For Advisory Committees.

November 23, 2001

ASCO To Begin Large Study On Quality Of Cancer Care.

January 28, 2000

NCCS Networker Volume 11 Issue 2, Summer 1997

June 13, 1997

NCI Funds; Ad Hoc Group Approves NCCTG Renewal

September 18, 1981